PureTech Health plc PRTC
Updated: 9 Aug 2026
No signal published yet
We already track PureTech Health and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow PureTech Health plc? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow PureTech Health free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
In July 2026, PureTech announced that its founded entity Celea Therapeutics dosed the first patient in the global Phase 3 SURPASS-IPF trial evaluating deupirfenidone for idiopathic pulmonary fibrosis. The study launch followed Celea's completion of a $180 million financing round to support pivotal development.
What Firelda Watch includes for PureTech Health plc
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow PureTech Health plc? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow PureTech Health free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more